Natco Pharma transfers Lenalidomide ANDA to Arrow International
4th Aug 2021

Natco Pharma has transferred the Lenalidomide Capsules ANDA (2.5mg, 5mg, 10mg, 15mg, 20mg and 25mg strengths) to Arrow International as per an earlier agreement between the parties. This transfer of the ANDA to Arrow does not materially change any of the terms of the agreement between the parties.

Arrow International (an affiliate of Teva Pharmaceutical Industries) is the marketing partner of NATCO for this product in the US market. The ANDA was approved by USFDA in May 2021 with final approval in the 5mg, 10mg, 15mg, and 25mg strengths, and tentative approval in the 2.5mg and 20mg strengths.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.